Secukinumab

Cosentyx

可善挺注射液劑

150mg/1mL/pre-filled pen

05.BIOLOGIC AND IMMUNOLOGIC AGENT; ;

05.05.IMMUNOLOGIC AGENT;;

Secukinumab selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.

1.斑塊性乾癬2.乾癬性關節炎3.中軸性脊椎關節炎4.兒童特發性關節炎(接骨點發炎相關型、兒童乾癬性) 5.化膿性汗腺炎

B 動物試驗中無法證實對胎兒有害，但沒有以人做較嚴謹的研究。或動物試驗報告對胎兒有害，但對懷孕婦女有對照組的研究中無法證明對胎兒有害。

Unknown

Ankylosing spondylitis:
loading dose 150 mg SC at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks.
Without a loading dose: 150 mg every 4 weeks.
consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis.
Axial spondyloarthritis(nonradiographic):
loading dose: SC 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks.
Plaque psoriasis:
Adult: 150-300 mg SC once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks.Some patients may only require 150 mg per dose.
Children ≥6 years and Adolescents <18 years:
BW<50 kg: SC 75 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 75 mg every 4 weeks
BW≥50 kg: SC 150 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks; some may require higher dose of 300 mg every 4 weeks
Psoriatic arthritis:
loading dose: 150 mg SC at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks; consider an increase to 300 mg in patients who continue to have active psoriatic arthritis.
Without a loading dose: 150 mg SC every 4 weeks; consider an increase to 300 mg in patients who continue to have active psoriatic arthritis .
Coexistent moderate to severe plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Some patients may only require 150 mg per dose.
Enthesitis-related arthritis
Children ≥6 years and Adolescents:
BW<50 kg: SC 75 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 75 mg every 4 weeks
BW≥50 kg: SC 150 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks
Hidradenitis suppurativa: SC 300 mg at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks; consider an increase to 300 mg every 2 weeks in patients who have an inadequate response.

Infection、Nasopharyngitis、upper respiratory tract infection、mucocutaneous candidiasis、Diarrhea、oral herpes、Urticaria

1.Serious infection 2.Tuberculosis

1.本品限皮下注射於大腿、腹部或上臂外側。不要在敏感會痛的、受傷的、發紅的、有硬塊的或有乾癬的皮膚部位注射。每次的注射部位都要不同。另注射部位須避開肚臍周圍5公分 的區域。
2本品須冷藏2-8℃,置於原包裝中避光儲存。
3本品於注射前須回溫至室溫(15至30分鐘)，回溫時勿拔開針頭套。由冰箱取出後，需在1小時內使用完畢，限單次使用。
4本品針頭套含有天然乳膠，可能會引起對乳膠過敏者的過敏反應
5本品不可搖晃,以避免起泡。

建立者

104784

建立時間

2018-05-15 08:33:30

維護者

103617

維護時間

2024-01-04 09:55:51